• Home
  • About Us
  • Inventors
  • Investors
  • Portfolio
  • Resources
  • Contact

Angel and Seed Funds

Angel and Seed Funds

An angel group or seed fund will help provide capital for an early stage (often pre-revenue) company, usually in exchange for convertible debt or ownership equity.

  • Portland Seed Fund
  • Elevate Capital
  • Willamette Valley Capital
  • Bridgeworks Capital
  • Aventurine
  • Chemical Angels
  • Element 8/E8 Angels
  • Cascade Seed Fund
  • Rogue Venture Partners
  • 1859 Ventures
  • Keirestu Forum/K4 Northwest
  • Bend Venture Conference
  • Angel Oregon (Oregon Entrepreneur's Network, OEN)

Discover More

  • ONAMI Entrepreneurs-in-Residence
  • Upcoming Events
  • Recent News
  • Where to Find Funding
    • Oregon Small Business Innovation Research (SBIR) Grants
    • Federal Small Business Innovation Research (SBIR) Grants
    • Angel and Seed Funds
    • Venture Capital Firms
    • Corporate Venture Arms
  • Locate an Accelerator near me
  • How can we help you?

Success Story

ONAMI portfolio company Agility Robotics Has Real Legs

Meet ONAMI portfolio company Agility Robotics founders

News

CorMic Tech Hub Awarded $45M

$45M for development and commercialization of microfluidics technology in Oregon

View News Stories

Events

FDA Programs to Facilitate and Expedite Development of New Drugs

OBI Virtual Lunch and Learn

Location
Online/Zoom
Date
Tuesday, July 15th, 2025

Search Upcoming Events

Contact Us

  • Call Skip Rung
  • 541-713-1331
  • skip@onami.us

© 2025 Oregon Nanoscience and Microtechnologies Institute. All Rights Reserved.

HOW CAN WE HELP?

Thank you

We've received your email and will respond shortly.

Sincerely,
The ONAMI Team

Please provide the information below and we’ll get right back to you.

Upcoming Event

FDA Programs to Facilitate and Expedite Development of New Drugs

FDA Programs to Facilitate and Expedite Development of New Drugs

Location
Online/Zoom

Join Dr. Elizabeth Gordon from 12 to 1pm for an engaging and informative Virtual Lunch & Learn series, where we will dive deep into the key aspects of drug development in the U.S. This is the last installment of our 3-part series designed to provide a comprehensive understanding of the critical steps, strategies, and regulatory considerations that drive successful pharmaceutical product development.

This session will present the mechanisms that exist to expedite approval of products to treat life-threatening diseases and conditions. The goal of these programs is to accelerate the availability of new therapies to patients with serious conditions, especially when there are no satisfactory alternatives. The benefits of each program will be reviewed, and the data requirements for successful application will be discussed.

There is no cost to participate, but registration is required!

Browse Upcoming Events